• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

4-[4-(4-氟苯基)-2-甲基-5-氧代-2,5-二氢异恶唑-3-基]-1-甲基吡啶碘化物 - 4-[3-(4-氟苯基)-2-甲基-5-氧代-2,5-二氢异恶唑-4-基]-1-甲基吡啶碘化物(0.6/0.4)

4-[4-(4-Fluoro-phen-yl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-3-yl]-1-methyl-pyridinium iodide-4-[3-(4-fluoro-phen-yl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-4-yl]-1-methyl-pyridinium iodide (0.6/0.4).

作者信息

Margutti Simona, Schollmeyer Dieter, Laufer Stefan

出版信息

Acta Crystallogr Sect E Struct Rep Online. 2007 Dec 18;64(Pt 1):o298-9. doi: 10.1107/S1600536807055985.

DOI:10.1107/S1600536807055985
PMID:21200862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2915348/
Abstract

The crystal structure of the title compound, C(16)H(16)FN(2)O(2) (+)·I(-), was determined as part of a study of the biological activity of isoxazolone derivatives as p38 mitogen-activated protein kinase (MAPK) inhibitors. The X-ray crystal structure of 4-[4-(4-fluoro-phenyl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-3-yl]-1-methyl-pyridinium iodide showed the presence of the regioisomer 4-[3-(4-fluoro-phenyl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-4-yl]-1-methyl-pyridinium iodide. The synthesis of the former compound was achieved by reacting 4-(4-fluoro-phenyl)-3-(4-pyridyl)isoxazol-5(2H)-one after treatment with Et(3)N in dimethyl-formamide, with iodo-methane. The unexpected formation of the regioisomer could be explained by a rearrangement occurring via aziridine of the isoxazolone compound. The regioisomers have site occupancies of 0.632 (4)/0.368 (4). The two six members rings make a dihedral angle of 66.8 (2)°.

摘要

作为异恶唑酮衍生物作为p38丝裂原活化蛋白激酶（MAPK）抑制剂的生物活性研究的一部分，测定了标题化合物C(16)H(16)FN(2)O(2) (+)·I(-)的晶体结构。4-[4-(4-氟苯基)-2-甲基-5-氧代-2,5-二氢异恶唑-3-基]-1-甲基吡啶碘化物的X射线晶体结构显示存在区域异构体4-[3-(4-氟苯基)-2-甲基-5-氧代-2,5-二氢异恶唑-4-基]-1-甲基吡啶碘化物。前一种化合物的合成是通过在二甲基甲酰胺中用Et(3)N处理4-(4-氟苯基)-3-(4-吡啶基)异恶唑-5(2H)-酮，然后与碘甲烷反应来实现的。区域异构体的意外形成可以通过异恶唑酮化合物通过氮丙啶发生的重排来解释。区域异构体的占有率为0.632 (4)/0.368 (4)。两个六元环的二面角为66.8 (2)°。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/f2a2142d8357/e-64-0o298-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/2b6c30250e73/e-64-0o298-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/1a6416b47a4e/e-64-0o298-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/b8d832b663ec/e-64-0o298-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/f2a2142d8357/e-64-0o298-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/2b6c30250e73/e-64-0o298-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/1a6416b47a4e/e-64-0o298-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/b8d832b663ec/e-64-0o298-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9168/2915348/f2a2142d8357/e-64-0o298-fig4.jpg

相似文献

1
4-[4-(4-Fluoro-phen-yl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-3-yl]-1-methyl-pyridinium iodide-4-[3-(4-fluoro-phen-yl)-2-methyl-5-oxo-2,5-dihydro-isoxazol-4-yl]-1-methyl-pyridinium iodide (0.6/0.4).4-[4-(4-氟苯基)-2-甲基-5-氧代-2,5-二氢异恶唑-3-基]-1-甲基吡啶碘化物 - 4-[3-(4-氟苯基)-2-甲基-5-氧代-2,5-二氢异恶唑-4-基]-1-甲基吡啶碘化物(0.6/0.4)
Acta Crystallogr Sect E Struct Rep Online. 2007 Dec 18;64(Pt 1):o298-9. doi: 10.1107/S1600536807055985.
2
4-(4-Fluoro-phen-yl)-2-methyl-3-(1-oxy-4-pyridyl)isoxazol-5(2H)-one.4-（4-氟苯基）-2-甲基-3-（1-氧代-4-吡啶基）异恶唑-5（2H）-酮
Acta Crystallogr Sect E Struct Rep Online. 2008 Jan 23;64(Pt 2):o504. doi: 10.1107/S1600536807066500.
3
Methyl 4-[5-(4-fluoro-phen-yl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfan-yl]butanoate.4-[5-(4-氟苯基)-4-(吡啶-4-基)-1H-咪唑-2-基硫烷基]丁酸甲酯
Acta Crystallogr Sect E Struct Rep Online. 2008 Jun 7;64(Pt 7):o1183-4. doi: 10.1107/S1600536808016000.
4
5-Butyl-amino-6-(4-fluoro-phen-yl)-7-oxo-1-p-tolyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidine-3-carbonitrile.5-丁基氨基-6-(4-氟苯基)-7-氧代-1-对甲苯基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-3-腈
Acta Crystallogr Sect E Struct Rep Online. 2008 Apr 16;64(Pt 5):o845. doi: 10.1107/S1600536808009744.
5
3-Methyl-4-{[(3-{[(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl-idene)(phen-yl)meth-yl]amino-meth-yl}benz-yl)amino](phen-yl)methyl-idene}-1-phenyl-1H-pyrazol-5(4H)-one.3-甲基-4-{[(3-{[(3-甲基-5-氧代-1-苯基-4,5-二氢-1H-吡唑-4-基亚基)(苯基)甲基]氨基甲基}苄基)氨基](苯基)亚甲基}-1-苯基-1H-吡唑-5(4H)-酮
Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67(Pt 8):o2015. doi: 10.1107/S1600536811027000. Epub 2011 Jul 13.
6
3-(4-Fluoro-phen-yl)-2-(4-methoxy-phen-oxy)-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile.3-（4-氟苯基）-2-（4-甲氧基苯氧基）-4-氧代-5-苯基-4,5-二氢-3H-吡咯并[3,2-d]嘧啶-7-腈
Acta Crystallogr Sect E Struct Rep Online. 2008 Aug 6;64(Pt 9):o1680. doi: 10.1107/S1600536808024410.
7
N-{4-[4-(4-Fluoro-phen-yl)-1-(2-methoxy-ethyl)-2-methyl-sulfanyl-1H-imidazol-5-yl]-2-pyrid-yl}-2-methyl-3-phenyl-propionamide.N-{4-[4-(4-氟苯基)-1-(2-甲氧基乙基)-2-甲基硫烷基-1H-咪唑-5-基]-2-吡啶基}-2-甲基-3-苯基丙酰胺
Acta Crystallogr Sect E Struct Rep Online. 2009 Nov 21;65(Pt 12):o3128. doi: 10.1107/S1600536809048661.
8
1,5-Dimethyl-4-{[(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl-idene)(thio-phen-2-yl)meth-yl]amino}-2-phenyl-1H-pyrazol-3(2H)-one.1,5-二甲基-4-{[(3-甲基-5-氧代-1-苯基-4,5-二氢-1H-吡唑-4-基亚基)(噻吩-2-基)甲基]氨基}-2-苯基-1H-吡唑-3(2H)-酮
Acta Crystallogr Sect E Struct Rep Online. 2011 Jan 22;67(Pt 2):o476-7. doi: 10.1107/S1600536811002467.
9
2-(2,4-Dichloro-phen-yl)-N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)acetamide.2-（2,4-二氯苯基）-N-（1,5-二甲基-3-氧代-2-苯基-2,3-二氢-1H-吡唑-4-基）乙酰胺
Acta Crystallogr Sect E Struct Rep Online. 2013 Jan 1;69(Pt 1):o39. doi: 10.1107/S1600536812049628. Epub 2012 Dec 8.
10
3-(4-Bromo-phen-yl)-3-(4-hydr-oxy-6-oxo-1,6-dihydro-pyrimidin-5-yl)-N-[(S)-1-phenyl-ethyl]propanamide.3-(4-溴苯基)-3-(4-羟基-6-氧代-1,6-二氢嘧啶-5-基)-N-[(S)-1-苯乙基]丙酰胺
Acta Crystallogr Sect E Struct Rep Online. 2009 Feb 6;65(Pt 3):o489. doi: 10.1107/S1600536809003821.

本文引用的文献

1
Substituted isoxazoles as potent inhibitors of p38 MAP kinase.取代异恶唑作为p38丝裂原活化蛋白激酶的有效抑制剂。
ChemMedChem. 2006 Feb;1(2):197-207. doi: 10.1002/cmdc.200500025.
2
An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays.一种与标准放射性液相测定法相当的免疫吸附、非放射性p38丝裂原活化蛋白激酶测定法。
Anal Biochem. 2005 Sep 1;344(1):135-7. doi: 10.1016/j.ab.2005.06.015.
3
The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
基于异恶唑酮的新型肿瘤坏死因子-α（TNF-α）生成抑制剂的研发。
Bioorg Med Chem Lett. 2005 May 2;15(9):2399-403. doi: 10.1016/j.bmcl.2005.02.066.
4
Potential of p38 inhibitors in the treatment of rheumatoid arthritis.p38抑制剂在类风湿关节炎治疗中的潜力。
Drug News Perspect. 2000 Oct;13(8):488-97.
5
From imidazoles to pyrimidines: new inhibitors of cytokine release.
J Med Chem. 2002 Jun 20;45(13):2733-40. doi: 10.1021/jm011098a.
6
SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.新型p38丝裂原活化蛋白激酶抑制剂4-羟基哌啶及羟烷基取代杂环的构效关系
Bioorg Med Chem Lett. 2000 Jun 5;10(11):1261-4. doi: 10.1016/s0960-894x(00)00200-6.
7
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.
Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6. doi: 10.1016/s0960-894x(98)00549-6.
8
Pyrroles and other heterocycles as inhibitors of p38 kinase.
Bioorg Med Chem Lett. 1998 Oct 6;8(19):2689-94. doi: 10.1016/s0960-894x(98)00495-8.
9
Structural basis of inhibitor selectivity in MAP kinases.丝裂原活化蛋白激酶中抑制剂选择性的结构基础。
Structure. 1998 Sep 15;6(9):1117-28. doi: 10.1016/s0969-2126(98)00113-0.